$NVFY
Nova Lifestyle, Inc. Stock $nvfy

$nvfy Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032905 Filed on November 18, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$2.250M	$3.016M	$2.917M
YoY Change	-25.38%	3.41%	-12.15%
Cost Of Revenue	$1.414M	$1.878M	$1.517M
YoY Change	-88.32%	23.82%	-84.69%
Gross Profit	$835.8K	$1.138M	$1.400M
YoY Change	-109.19%	-18.71%	-121.24%
Gross Profit Margin	37.15%	37.72%	47.99%
Selling, General & Admin	$1.857M	$2.092M	$2.441M
YoY Change	-26.13%	-14.31%	47.93%
% of Gross Profit	222.19%	183.85%	174.41%
Research & Development	$590.00	$660.00	$105.5K
YoY Change	1375.0%	-99.37%
% of Gross Profit	0.07%	0.06%	7.54%
Depreciation & Amortization	$26.18K	$19.95K	$23.53K
YoY Change	12.65%	-15.22%	135.3%
% of Gross Profit	3.13%	1.75%	1.68%
Operating Expenses	$1.858M	$2.092M	$2.546M
YoY Change	-26.11%	-17.85%	54.33%
Operating Profit	-$1.022M	-$954.0K	-$1.147M
YoY Change	-91.19%	-16.82%	-86.08%
Interest Expense	-$50.77K	-$759.1K	-$82.26K
YoY Change	-450.38%	822.78%	64.52%
% of Operating Profit
Other Income/Expense, Net	$470.00	-$759.0K
YoY Change	-99.6%
Pretax Income	-$8.771M	-$1.713M	-$1.229M
YoY Change	-23.55%	39.37%	-85.19%
Income Tax	$2.400K		$167.5K
% Of Pretax Income
Net Earnings	-$8.799M	-$1.713M	-$1.397M
YoY Change	-23.2%	22.65%	-82.93%
Net Earnings / Revenue	-391.11%	-56.79%	-47.89%
Basic Earnings Per Share		-$0.25	-$0.22
Diluted Earnings Per Share	-$1.24	-$247.1K	-$218.3K
COMMON SHARES
Basic Shares Outstanding	6.950M shares	6.882M shares	6.399M shares
Diluted Shares Outstanding		1.387M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.374M	$3.170M	$7.879M
YoY Change	-78.1%	-59.76%	-15.73%
Cash & Equivalents	$1.374M	$3.170M	$7.879M
Short-Term Investments
Other Short-Term Assets	$1.526M	$352.2K	$863.8K
YoY Change	37.01%	-59.23%	57.05%
Inventory	$4.933M	$12.76M	$27.78M
Prepaid Expenses	$1.505M	$309.4K
Receivables	$288.5K	$389.9K	$185.4K
Other Receivables	$79.18K	$30.25K	$657.2K
Total Short-Term Assets	$8.200M	$16.70M	$37.36M
YoY Change	-67.93%	-55.29%	-36.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$368.6K	$383.4K	$2.464M
YoY Change	-27.82%	-84.44%	-17.32%
Goodwill	$218.6K	$218.6K
YoY Change	0.0%
Intangibles	$13.84K
YoY Change	-27.96%
Long-Term Investments
YoY Change
Other Assets	$71.15K	$69.73K	$72.57K
YoY Change	-2.06%	-3.91%	-61.81%
Total Long-Term Assets	$3.333M	$3.392M	$2.755M
YoY Change	-15.84%	23.13%	-18.73%
TOTAL ASSETS
Total Short-Term Assets	$8.200M	$16.70M	$37.36M
Total Long-Term Assets	$3.333M	$3.392M	$2.755M
Total Assets	$11.53M	$20.10M	$40.12M
YoY Change	-60.94%	-49.91%	-35.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$321.3K	$928.5K	$716.5K
YoY Change	-10.35%	29.58%	19.42%
Accrued Expenses	$1.064M	$955.9K	$959.7K
YoY Change	15.58%	-0.4%	18.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.643M	$2.211M	$2.348M
YoY Change	-9.46%	-5.84%	7.73%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K	$150.0K
YoY Change	0.0%	0.0%	0.0%
Other Long-Term Liabilities	$3.129M	$3.294M	$2.883M
YoY Change	-24.07%	14.26%	-18.78%
Total Long-Term Liabilities	$3.279M	$3.444M	$3.033M
YoY Change	-23.23%	13.55%	-18.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.643M	$2.211M	$2.348M
Total Long-Term Liabilities	$3.279M	$3.444M	$3.033M
Total Liabilities	$4.922M	$5.656M	$5.382M
YoY Change	-19.12%	5.09%	-8.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.71M	-$27.91M
YoY Change	87.23%
Common Stock	$7.199K	$43.15M
YoY Change	-99.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.612M	$14.44M	$34.74M
YoY Change
Total Liabilities & Shareholders Equity	$11.53M	$20.10M	$40.12M
YoY Change	-60.94%	-49.91%	-35.77%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$8.799M	-$1.713M	-$1.397M
YoY Change	-23.2%	22.65%	-82.93%
Depreciation, Depletion And Amortization	$26.18K	$19.95K	$23.53K
YoY Change	12.65%	-15.22%	135.3%
Cash From Operating Activities	-$1.914M	-$2.132M	-$1.515M
YoY Change	15.79%	40.75%	-7672.8%
INVESTING ACTIVITIES
Capital Expenditures	$3.000K	-$4.280K	-$2.210K
YoY Change	782.35%	93.67%	-99.39%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.000K	-$4.280K	$1.218M
YoY Change	-982.35%	-100.35%	-438.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	2.761M
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-1.914M	-2.132M	-1.515M
Cash From Investing Activities	-3.000K	-4.280K	1.218M
Cash From Financing Activities	0.000	0.000	2.761M
Net Change In Cash	-1.917M	-2.136M	2.464M
YoY Change	16.0%	-186.67%	-824.83%
FREE CASH FLOW
Cash From Operating Activities	-$1.914M	-$2.132M	-$1.515M
Capital Expenditures	$3.000K	-$4.280K	-$2.210K
Free Cash Flow	-$1.917M	-$2.127M	-$1.512M
YoY Change	15.95%	40.67%	-497.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Net Income Loss NetIncomeLoss	-8505696	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1712992	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001473334
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2021Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2021Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	NVFY	Deregistration And Liquidation Of Closed Subsidiary Nova Macau DeregistrationAndLiquidationOfClosedSubsidiaryNovaMacau		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2021Q4	NVFY	Accrued Auditing AccruedAuditing		usd
	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36259
	dei	Entity Registrant Name EntityRegistrantName	NOVA LIFESTYLE, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0746568
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6565 E. Washington Blvd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Commerce
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90040
	dei	City Area Code CityAreaCode	(323)
	dei	Local Phone Number LocalPhoneNumber	888-9999
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	NVFY
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6950260	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3170102	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6276106	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	389943	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	103397	usd
CY2022Q3	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	42802	usd
CY2021Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	707264	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	12760772	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	17656175	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	309359	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	406366	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	30245	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	120634	usd
CY2022Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	949	usd
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	299011	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	16704172	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	25568953	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	383408	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	510680	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2720438	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3158734	usd
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	69729	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	72651	usd
CY2022Q3	us-gaap	Goodwill Goodwill	218606	usd
CY2021Q4	us-gaap	Goodwill Goodwill	218606	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	3392181	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3960671	usd
CY2022Q3	us-gaap	Assets Assets	20096353	usd
CY2021Q4	us-gaap	Assets Assets	29529624	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	928452	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	358362	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	740635	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	731284	usd
CY2022Q3	NVFY	Advance From Customers Current AdvanceFromCustomersCurrent	178507	usd
CY2021Q4	NVFY	Advance From Customers Current AdvanceFromCustomersCurrent	394376	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	362356	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	326679	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	1389	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3696	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2211339	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1814397	usd
CY2022Q3	us-gaap	Other Loans Payable OtherLoansPayable	150000	usd
CY2021Q4	us-gaap	Other Loans Payable OtherLoansPayable	150000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2136793	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2577567	usd
CY2022Q3	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	1157603	usd
CY2021Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	1543472	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3444396	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4271039	usd
CY2022Q3	us-gaap	Liabilities Liabilities	5655735	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6085436	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6951049	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6951049	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6836742	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6836742	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	6951	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6837	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	43147149	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	42660383	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-806054	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	381850	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27907428	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19604882	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	14440618	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23444188	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20096353	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29529624	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10495097	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9798154	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3016104	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2916571	usd
	us-gaap	Cost Of Revenue CostOfRevenue	11377203	usd
	us-gaap	Cost Of Revenue CostOfRevenue	11025436	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	1878361	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	1517032	usd
	us-gaap	Gross Profit GrossProfit	-882106	usd
	us-gaap	Gross Profit GrossProfit	-1227282	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1137743	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	1399539	usd
	us-gaap	Selling Expense SellingExpense	2181750	usd
	us-gaap	Selling Expense SellingExpense	2970745	usd
CY2022Q3	us-gaap	Selling Expense SellingExpense	643206	usd
CY2021Q3	us-gaap	Selling Expense SellingExpense	1323903	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4401272	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3993521	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1448535	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1222478	usd
	us-gaap	Operating Expenses OperatingExpenses	6583022	usd
	us-gaap	Operating Expenses OperatingExpenses	6964266	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2091741	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2546381	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7465128	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8191548	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-953998	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1146842	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	84	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	84	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-36549	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-644525	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	32657	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-708169	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1771	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-8220	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-5844	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2261	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-31755	usd
	NVFY	Financial Expenses FinancialExpenses	148208	usd
	NVFY	Financial Expenses FinancialExpenses	160368	usd
CY2022Q3	NVFY	Financial Expenses FinancialExpenses	48648	usd
CY2021Q3	NVFY	Financial Expenses FinancialExpenses	48732	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-837418	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-133555	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-758994	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-82258	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8302546	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8325103	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1712992	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1229100	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	180593	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167532	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8302546	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	62110	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1712992	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1396632	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-994394	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-484738	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-699802	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-91974	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9296940	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8990434	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2412794	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1488606	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6885213	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5870632	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6932931	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6399158	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.45
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16874002	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3300	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	169620	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-893312	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	14440618	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	33452387	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2970	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	9900	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2760973	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-91974	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1396632	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	34737624	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23444188	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	9900	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	476980	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1187904	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8302546	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	14440618	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	40928475	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	8910	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	29700	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2760973	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-484738	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8505696	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	34737624	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8302546	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8505696	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	62055	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	632766	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	380178	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-36549	usd
	us-gaap	Inventory Write Down InventoryWriteDown	5169347	usd
	us-gaap	Inventory Write Down InventoryWriteDown	5526307	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	486880	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	38610	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2376	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-3328	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	295163	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-332870	usd
	us-gaap	Increase Decrease In Materials And Supplies IncreaseDecreaseInMaterialsAndSupplies	-664462	usd
	us-gaap	Increase Decrease In Materials And Supplies IncreaseDecreaseInMaterialsAndSupplies	-56440	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1706482	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	491056	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-175225	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	387526	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-632766	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-348917	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	570090	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27270	usd
	NVFY	Increase Decrease In Advance From Customers IncreaseDecreaseInAdvanceFromCustomers	-215869	usd
	NVFY	Increase Decrease In Advance From Customers IncreaseDecreaseInAdvanceFromCustomers	137243	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-12731	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	171218	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-87807	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-70473	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3453559	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3129345	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5771	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	155156	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5771	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-155156	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2760973	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2760973	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	353326	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-342380	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3106004	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-865908	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6276106	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8744784	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3170102	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7878876	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	247898	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	251067	usd
	us-gaap	Interest Paid Net InterestPaidNet	9016	usd
	us-gaap	Interest Paid Net InterestPaidNet	4801	usd
CY2020Q1	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	2500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zlSYc1y7IK04" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_863_z5apH3i1zgO7">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In preparing consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the dates of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include, but are not limited to, revenue recognition, the allowance for bad debt, valuation of inventories, the valuation of stock-based compensation, income taxes and unrecognized tax benefits, valuation allowance for deferred tax assets, assumptions used in assessing impairment of long-lived assets and goodwill, and loss contingencies. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The COVID-19 pandemic has created and may continue to create significant uncertainty in macroeconomic conditions, which may cause further business slowdowns or shutdowns, supply chain disruption, depress demand for the Company’s products, and adversely impact its results of operations. During the nine months ended September 30, 2022, the Company continued to face increasing uncertainties around its estimates of revenue collectability, accounts receivable credit losses and valuation of inventories. The Company expects uncertainties around its key accounting estimates to continue to evolve depending on the duration and degree of impact associated with the COVID-19 pandemic. Its estimates may change as new events occur and additional information emerges, and such changes <span style="background-color: white">will be</span> recognized or disclosed in its unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1044	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2376	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3420	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2376	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-3328	usd
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1316	usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	262	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	180593	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10328	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	110251	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	660	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	105460	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167532	usd
CY2022Q3	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	26700000	usd
CY2021Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	26700000	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	900	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	900	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	935	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	21	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	7	usd
	us-gaap	Advertising Expense AdvertisingExpense	857548	usd
	us-gaap	Advertising Expense AdvertisingExpense	1122959	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	237875	usd
CY2021Q3	us-gaap	Advertising Expense AdvertisingExpense	299012	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8302546	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8505696	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1712992	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1396632	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6885213	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5870632	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6932931	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6399158	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.45
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	56779	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	44279	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_z4h7HWbLTTcd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_868_zTCMX3yxFrQj">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial instruments that potentially subject the Company to credit risk consist primarily of accounts and other receivables. The Company does not require collateral or other security to support these receivables. The Company conducts periodic reviews of the financial condition and payment practices of its customers to minimize collection risk on accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">No customer accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zax36y0grV58"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zecbxZQjgH2d">10</span></span>% or more of the Company’s sales for the nine and three months ended September 30, 2022. No customer accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zynCxk8G0Tx4"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zBnBTsaIBr5h">10</span></span>% of the Company’s sales for the nine months ended September 30, 2021, while one customer accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zz8ltEUcK183" title="Concentration risk percentage">15</span>% of the Company’s sales for the three months ended September 30, 2021. Two customers accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYjDOcvFCJvg" title="Concentration risk percentage">64</span>% and<span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2WpOdOvvmIf" title="Concentration risk percentage"> 13</span>%, respectively, of the Company’s gross accounts receivable as of September 30, 2022. Four customers accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs1RbsnWoOe" title="Concentration risk percentage">22</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--TwoCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zd6kzqOJxUPi" title="Concentration risk percentage">19</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdbZmNCyg92e" title="Concentration risk percentage">14</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FourCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znajiyQgIyI2" title="Concentration risk percentage">14</span>%, respectively, of the Company’s gross accounts receivable as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company purchased its products from two and three major vendors during the nine months ended September 30, 2022 and 2021, respectively, accounting for a total of <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoVendorsMember_zymAkmYFgqu6" title="Concentration risk percentage">45</span>% for 2022 (<span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zMkB73e0jRr6" title="Concentration risk percentage">23</span>%, and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zuRekAQTQw4i" title="Concentration risk percentage">22</span>%) and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeVendorsMember_zLbPNlJBVKT1" title="Concentration risk percentage">56</span>% for 2021 (<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_za9GMNpeYu9b" title="Concentration risk percentage">25</span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zEzUAj0SBXJk" title="Concentration risk percentage">18</span>%, and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_zGdTUi7hEObe" title="Concentration risk percentage">13</span>%) of the Company’s purchases. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company purchased its products from three major vendors during the three months ended September 30, 2022 and 2021, accounting for a total of <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeVendorsMember_zq21Eyl0SYu3">62</span>% for 2022 (<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zpTepMXl5Lv9">25</span>%,<span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zPEEiQDbT59l" title="Concentration risk percentage"> 25</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_zq4hPMLlwVn7" title="Concentration risk percentage">12</span>%) and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeVendorsMember_zrb3zLdWdNg5">56</span>% for 2021 (<span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zRp6XDddwatb" title="Concentration risk percentage">21</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zUYEDZcXbRw" title="Concentration risk percentage">18</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_zK9F0aXgGvD6" title="Concentration risk percentage">17</span>%) of the Company’s purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances made to these vendors were $<span id="xdx_90F_ecustom--AdvancesToSuppliers_iI_c20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zY12bBPCuz45" title="Advances made to suppliers">8,899 </span>and $<span id="xdx_900_ecustom--AdvancesToSuppliers_iI_c20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zDae1b5sVir3">307,718</span> as of September 30, 2022 and December 31, 2021, respectively. Accounts payable to these vendors were $<span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pp0p0_c20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zY9TAWXilVm6" title="Accounts payable to suppliers">219,097</span> and $<span id="xdx_903_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zHg6dmPoQ8Gi" title="Accounts payable to suppliers">125,636</span> as of September 30, 2022 and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Depreciation Depreciation	19949	usd
CY2021Q3	us-gaap	Depreciation Depreciation	23529	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	12760772	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	17656175	usd
	us-gaap	Inventory Write Down InventoryWriteDown	5169347	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	50293	usd
	us-gaap	Inventory Write Down InventoryWriteDown	5526307	usd
CY2021Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	879616	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	961198	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	496208	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	450518	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	383408	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	510680	usd
	us-gaap	Depreciation Depreciation	62110	usd
	us-gaap	Depreciation Depreciation	62055	usd
CY2022Q3	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	42802	usd
CY2021Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	707264	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	309359	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	406366	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	30245	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	120634	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	339604	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	527000	usd
CY2022Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	6493	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	6893	usd
CY2022Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6442	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6231	usd
CY2022Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	141945	usd
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	134173	usd
CY2022Q3	NVFY	Accrued Auditing AccruedAuditing	20000	usd
CY2022Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	85221	usd
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	66507	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	102255	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	112875	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	362356	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	326679	usd
CY2020Q2	us-gaap	Proceeds From Loans ProceedsFromLoans	139802	usd
CY2020Q2	us-gaap	Debt Instrument Description DebtInstrumentDescription	The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. On June 5, 2020, Congress passed a new law that allowed current PPP borrowers to choose to extend the eight-week period to 24 weeks to use the funds, but which cannot be extended beyond December 31, 2020.
	us-gaap	Operating Lease Cost OperatingLeaseCost	603764	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	213477	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	203388	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	210874	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	807868	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	754510	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	701142	usd
CY2022Q3	NVFY	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	598820	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3073214	usd
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	632766	usd
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	210922	usd
CY2018Q4	us-gaap	Loss Contingency Allegations LossContingencyAllegations	On December 28, 2018, a federal putative class action complaint was filed by George Barney against the Company and its former and current CEOs and CFOs (Thanh H. Lam, Ya Ming Wong, Jeffery Chuang and Yuen Ching Ho) in the United States District Court for the Central District of California, claiming the Company violated federal securities laws and pursuing remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 (the “Barney Action”). Richard Deutner and ITENT EDV were subsequently appointed as lead plaintiffs and, on June 18, 2019, filed an Amended Complaint
CY2018Q4	us-gaap	Loss Contingency Actions Taken By Plaintiff LossContingencyActionsTakenByPlaintiff	Plaintiffs seek to represent a class of entities acquiring Nova’s stock from December 3, 2015 through December 20, 2018. They claim that during this period the Company: (1) overstated its purported strategic alliance with a customer in China to operate as lead designer and manufacturer for all furnishings in its planned $460 million senior care center in China; and (2) inflated sales in 2016 and 2017 by recognizing significant sales to two allegedly non-existent customers.
CY2022Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	750000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	340500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.97
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P1Y3M25D
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	340500	shares
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.97
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P1Y3M25D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	206500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.87
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	134000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.58
	NVFY	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm	P1Y6M29D
CY2022Q3	NVFY	Share Based Compensation Arrangement By Share Based Payment Awards Option Vested And Expected To Vest Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionVestedAndExpectedToVestExercisable	134000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1225959	shares
CY2021Q4	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.50
	NVFY	Share Based Weighted Average Remaining Contractual Term Outstanding ShareBasedWeightedAverageRemainingContractualTermOutstanding	P5Y7D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1225959	shares
CY2022Q3	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.50
	NVFY	Share Based Weighted Average Remaining Contractual Term Outstanding1 ShareBasedWeightedAverageRemainingContractualTermOutstanding1	P4Y3M7D
	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable1	1225959	shares
	NVFY	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	3.50
	NVFY	Share Based Weighted Average Remaining Contractual Term Exercisable ShareBasedWeightedAverageRemainingContractualTermExercisable	P4Y3M7D
CY2022Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.97
	NVFY	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm	P0Y9M25D
CY2022Q3	NVFY	Intrinsic Value Off Stock Options IntrinsicValueOffStockOptions	0.74
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
	us-gaap	Revenues Revenues	10495097	usd
	us-gaap	Revenues Revenues	9798154	usd
CY2022Q3	us-gaap	Revenues Revenues	3016104	usd
CY2021Q3	us-gaap	Revenues Revenues	2916571	usd
CY2022Q3	us-gaap	Noncurrent Assets NoncurrentAssets	3103846	usd
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	3669414	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	640430	usd

Files In Submission

Name	View Source	Status
0001493152-22-032905-index-headers.html	Edgar Link	pending
0001493152-22-032905-index.html	Edgar Link	pending
0001493152-22-032905.txt	Edgar Link	pending
0001493152-22-032905-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvfy-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
nvfy-20220930_cal.xml	Edgar Link	unprocessable
nvfy-20220930_def.xml	Edgar Link	unprocessable
nvfy-20220930_lab.xml	Edgar Link	unprocessable
nvfy-20220930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVFY
Nova Lifestyle, Inc. Stock $nvfy

2022 Q4 Form 10-Q Financial Statement

#000149315222032905 Filed on November 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVFY Nova Lifestyle, Inc. Stock $nvfy

2022 Q4 Form 10-Q Financial Statement

#000149315222032905 Filed on November 18, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVFY
Nova Lifestyle, Inc. Stock $nvfy